Product Images Losartan Potassium

Losartan Potassium is a medication that comes in the form of a 50mg tablet. The package contains 30 tablets and should be stored at a temperature between 20-25°C. The medication is packaged by RemedyRepack Inc. and the manufacturer is Alembic Pharma. The medication is RX only and the NDC number is 70518-3305-01. Additionally, the medication should be kept out of reach of children. The package insert should be consulted for directions on how to use the medication.*

This is a prescription drug called Losartan Potassium, which comes in a tablet form and contains 50mg of the active ingredient. It is packaged by RemedyRepack and expires on a variable date. The National Drug Code (NDC) for this product is 70518-3305-00, and it is manufactured by Alembic Pharma in Bridgewater, NJ. The recommended storage temperature is between 20-25°C (68-77°F), with acceptable excursions of 15-10°C (59-86°F), refer to USP. The package insert contains directions for use, and it is essential to keep this medication out of the reach of children.*

This is a statistical analysis of the effectiveness of two medications, Atenolol and Losartan Potassium Tablets, in reducing the primary endpoint for a group of patients. The adjusted risk reduction for Losartan Potassium Tablets was 13%, but it is unclear if this is statistically significant due to a p-value of .0.21. This information is presented in a graph that shows the study month on the x-axis and the percentage of patients with the primary endpoint on the y-axis.*

The text describes the comparison of the effect of Atenolol and Losartan Potassium Tablets on patients with fatal/non-fatal stroke. It shows that Losartan Potassium Tablets had a 25% adjusted risk reduction compared to Atenolol with a p-value of 0.001. The data suggests that Losartan Potassium Tablets may be a more effective treatment option for reducing the risk of stroke. The rest of the text shows the duration of the study in months.*

The text appears to be a table with data related to a study on the effects of losartan potassium and atenolol on stroke prevention within various demographic subgroups. The table includes data on primary endpoint events, rates, ratios, and demographic factors such as age, gender, race, hypertension, and diabetes. However, without more context it is difficult to provide a more specific description of the text.*

This is a graph displaying the results of a clinical trial comparing the effectiveness of Losartan Potassium Tablets to placebo in reducing the risk of an event in patients. The graph shows that of the total patients in the study, 60% experienced an event. The risk reduction achieved by using Losartan Potassium Tablets was 16.1% compared to the placebo group. The statistical significance of the findings was confirmed with a p-value of 0.022. However, without further information on the type of event and patient population studied, it is difficult to draw conclusions about the overall clinical significance of the findings.*